BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 13.88B |
| Revenue (ttm) | 353.78M |
| Net Income (ttm) | -797.12M |
| Shares Out | 192.71M |
| EPS (ttm) | -4.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 524,469 |
| Open | 71.06 |
| Previous Close | 71.72 |
| Day's Range | 70.93 - 72.28 |
| 52-Week Range | 25.34 - 72.28 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 74.79 (+3.86%) |
| Earnings Date | Oct 29, 2025 |
About BBIO
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t... [Read more]
Financial Performance
In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price target is $74.79, which is an increase of 3.86% from the latest price.
News
BridgeBio to Participate in December Investor Conferences
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio Pharma: Set For New Commercial Launches After Trial Successes
BridgeBio has surged 90% since April 2025, driven by major clinical trial successes and robust commercial execution. BBIO's BBP-418 and Encaleret trials both exceeded expectations, each targeting bill...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript
BridgeBio Pharma, Inc. ( BBIO) UBS Global Healthcare Conference 2025 November 10, 2025 1:15 PM EST Company Participants Chinmay Shukla Ananth Sridhar - Chief Operating Officer of Cardiorenal Anna Wad...
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared t...
National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry
Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enfor...
BridgeBio to Participate in November Investor Conferences
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announce...
BridgeBio Pharma: Bullish On Attruby's Momentum And 2026 Catalysts
BBIO's Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer's Tafamidis and Alnylam's Amvuttra. Its US uptake keeps...
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. ( BBIO) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Chinmay Shukla Neil Kumar - Co-Founder, CEO & Director Matthew Outten - Chief Commercial Officer...
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
PALO ALTO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript
BridgeBio Pharma, Inc. ( BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study October 29, 2025 8:00 AM EDT Company Participants Neil Kumar - Co-Founder, CEO & Director Ana...
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
- The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered encal...
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 October 27, 2025 8:00 AM EDT Company Participants Neil Kumar - C...
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company's prior studies
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today an...
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 vers...
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announc...
BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call Company Participants Ananth Sridhar Conference Call Participants Rachel Gafni Scott Adler Tyle...
BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Neil Kumar - Co-Founder, CEO & Director Presentation Un...
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0%...
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today a...
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announc...